Key result
Following Rotarix vaccine introduction, group A rotavirus prevalence among hospitalized children with acute gastroenteritis decreased from 11.3% in the first year to 6.8% in the second year.
Observational (n=850)
Absolute Event Rate: 6.8% vs 11.3%
The introduction of the monovalent rotavirus vaccine in Saudi Arabia was associated with a significant decrease in RVA gastroenteritis cases and a shift in circulating genotypes.
Supports RVA vaccination programs in reducing pediatric hospitalizations; leaves open need for prospective genotype surveillance studies.
This study aimed to investigate the prevalence of group A rotavirus (RVA) gastroenteritis and the distribution of the RVA genotypes as well as to determine a possible change in the age of occurrence of the RVA infection in the first 2 years after Rotarix® vaccine introduction in Saudi Arabia. This descriptive study included 850 hospitalized children <5 years of age with acute gastroenteritis (AG) between October 2013 and September 2015. Overall, 78 (9.2%) children were positive for RVA during the study period with a positivity rate ranging from 11.3% in the first year of the study to 6.8% in the second year. G1 (47.4%) was the predominant G type, followed by G2 (28.2%) and G9 (10.3%). The most common P type was P[8] (69.2%) followed by P[4] (25.6%). The decrease in the prevalence of G1P[8] from 51% to 37.1% was associated with an increase in the prevalence of G2P[4] from 21.6% to 33.3% during the 2-year study period. This study demonstrated a significant decrease in the prevalence of RVA-AG cases in the first 2-year period after vaccine introduction, especially in the age group between 1 and 12 months, and a reduction in the circulation of G1P[6]. The parallel rise and spread of G2P[4] in post-vaccination period might pose an impact to long-term vaccine efficacy. Continued surveillance studies in different Saudi regions are crucial to document the effectiveness of Rotarix® vaccine and evaluate the potential emergence of rare/novel RVA genotypes. J. Med. Virol. 89:429-434, 2017.
No takes yet. Share an insight, caveat, or question.
Al-Ayed et al. (2016) conducted an observational in acute gastroenteritis (n=850). Rotarix vaccine introduction vs. First year of study was evaluated on Group A rotavirus (RVA) positivity. Following Rotarix vaccine introduction, group A rotavirus prevalence among hospitalized children with acute gastroenteritis decreased from 11.3% in the first year to 6.8% in the second year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: